Azilsartan as “Add-On” Treatment with Methotrexate Improves the Disease Activity of Rheumatoid Arthritis

Table 7

Effect of azilsartan (Azil) on the hematopoietic function markers of patients with active RA maintained on methotrexate (MTX).

Parameters	MTX + placebo		MTX + Azil
	Baseline	After 90 days	Baseline	After 90 days
Hb (g/dL)
WBC count ×10^3 cells/μL
Platelets count ×10^9 cells/L

Values were presented as mean ± S.D; : number of patients; different compared with baseline within the same group ; values with different superscripts (a, b) within each parameter were significantly different .